One oligopeptide derived from the C terminus, PQIP-PPYVEPT (amino acids 115 to 125), was capable of inhibiting PA, suggesting that this peptide carries the cross-reactive epitope. A homologous sequence was found in the VZV gene 22 protein by database analysis, and the oligopeptide TNIPPPLALLR (amino acids 1330 to 1340) had the ability to inhibit PA. These findings suggest that some IgM antibodies against the VZV gene 22 protein produced in the early phase of VZV infection are cross-reactive with the HTLV-1 gag p19 protein because they recognize an antigenic determinant containing an IPPP tetrapeptide.
During the course of epidemiological studies on infections of humans with human T cell leukaemia virus type 1 (HTLV-1), we have observed that sera from patients recently infected with varicella-zoster virus (VZV) often gave a positive reaction in one of the serological tests for HTLV-1 antibody, the particle agglutination (PA) test. This test is conventionally carried out with HTLV-1 antigen-coated gelatin particles (Ikeda et al., 1984) and currently is in use for the routine screening of blood for HTLV-1 antibody in Japan. The frequent occurrence of positive reactions with anti-VZV sera may have important practical as well as biological implications. Therefore, we examined the mechanism of cross-reactivity between anti-VZV sera and HTLV-1, and found a common epitope in VZV and HTLV-1 proteins recognized by anti-VZV IgM antibodies.
Paired serum specimens from 60 patients showing significant increases (generally fourfold or more) in anti-VZV titre in the complement fixation (CF) test were examined for HTLV-1 PA reactivity. A significant rise in PA antibody titre was observed with paired sera from 16 patients (Table 1) . However, all these sera were confirmed to be negative for HTLV-1 antibody in the indirect immunofluorescence (IF) test (Hinuma et al., 1981) . These results suggested that some antibodies produced in primary VZV infections are cross-reactive 0001-1136 0001- © 1992 with HTLV-1 antigen(s). Therefore the cross-reactive antibodies might be of the IgM class.
To confirm this idea 40 sera known to contain anti-VZV IgM antibody were examined. All of these sera were negative in standard serological tests for HTLV-I antibodies, i.e. the IF test (Hinuma et al., 1981) and ELISA (Taguchi et al., 1983) . Of these 40 anti-VZV sera, 13 were found to be positive in the PA test with antibody titres ranging from 1:40 to 1 : 1280. When the 13 PApositive sera were treated with 25 mM-2-mercaptoethanol, known to inactivate IgM antibodies, PA reactivity was completely abolished (data not shown). We also examined the PA reactivity of sera containing IgM antibodies against other viruses. These included 12 against herpes simplex virus type 1 (HSV-I), 13 against cytomegalovirus (CMV), 17 against mumps virus, 14 against measles virus, 18 against rubella virus, 19 against Epstein-Barr virus (EBV) and 10 against human herpesvirus 6 (HHV-6) (kindly supplied by Dr K. Yamanishi). None of these sera were PA-positive. Collectively, these results indicated that some anti-VZV IgM antibodies are specifically cross-reactive with HTLV-1 antigen(s) in the PA test.
To confirm this cross-reactivity, a PA inhibition test was performed with VZV antigens (Table 2) . PA titres of PA-positive anti-VZV sera were markedly diminished * wi-38 cells (ATCC no. CCL75) were infected with VZV (Kawaguchi strain), CMV (Towne strain) or HSV-I (HF strain). The infected cells were harvested when c.p.e, was observed in > 80% of the monolayer, sonicated at 1 x 107 cells/ml in PBS for 2 min, mixed with 1 volume of serum and incubated for I h at 37 °C before the PA test. MT-2 cells producing HTLV-1 antigens served as a positive control, and Molt-4 cells and WI-38 cells as uninfected controls.
by pre-incubation with a lysate of WI-38 cells infected with VZV, but not with one from WI-38 cells infected with HSV-1. A twofold decrease in the P A titre was also observed with the C M V -i n f e c t e d cell extract. This might indicate that a C M V protein(s) is also weakly cross- from HTLV-l-infected MT-2 cells was carried out as described (Sato et aL, 1990) . The blots were first incubated with anti-VZV sera, the PA titres of which were 1280, 640 and < 10, respectively (lanes I to 3), or an anti-HTLV-1 serum (lane 4), then with HRP-conjugated anti-human IgG (?-chain specific) (a) or anti-human IgM ~-chain specific) (b) and visualized using a Konica immunostaining HRP kit.
reactive with PA-reactive a n t i -V Z V I g M antibodies. P A titres of anti-HTLV-1 sera were not decreased by any of these lysates; however the P A reactivities of these sera were completely abolished by the cell lysate of HTLV-1-positive M T -2 cells . These observations further supported the idea that V Z Vspecific antibodies are responsible for the cross-reactivity with HTLV-1 antigens.
To identify the c o m p o n e n t of the HTLV-1 antigens recognized by cross-reactive a n t i -V Z V I g M antibodies, Western blot (WB) analysis was performed. Fig. 1 shows representative results. W h e n horseradish peroxidase ( H R P ) -c o n j u g a t e d a n t i -h u m a n I g M was used as the second antibody, the p19 and p28 bands were stained by PA-positive a n t i -V Z V sera (Fig. l b ; lanes 1 and 2) and an H T L V -l -p o s i t i v e serum (lane 4), but not by a PA-negative a n t i -V Z V serum (lane 3). W h e n H R P -c o njugated a n t i -h u m a n I g G was used as the second a n t i b o d y (Fig. 1 a) , no reactive b a n d was observed for any anti-V Z V sera, including PA-positive ones, whereas various H T L V -l -s p e c i f i c bands, including p19 and p28, were strongly stained by an anti-HTLV-1 serum. Since the p28 and vpr-pl9M. Since the HIV-I vpr protein had been expressed previously and the vpr antigen detection system had been established (Sato et al., 1990) , a vpr-pl9 fusion protein was developed. Plasmid pGEMEX-I (Promega) was ligated to the vpr gene fragment of pUCll8NR (Sato et al., 1990 ) and the HTLV-1 gag gene fragment of p7.5gagN (Nam et al., 1988) . The plasmid thus constructed, pGEMEXRpl9, produced a fusion protein, vpr-pl9, having the Nterminal 76 amino acids of vpr, amino acids 17 to 130 of the gag pl9 protein and amino acids 131 to 144 of the gag p24 protein. By oligonucleotide-directed site-specific mutagenesis, a stop codon (TAG) was created at codon 114 (GAT) of the pl9 gene in plasmid pGEMEXRpI9M, which produced the C-terminal-truncated fusion protein vpr-pl9M. Four synthetic peptides derived from the Cterminal region of HTLV-1 pl 9 are indicated by bars (see Table 3a ). del indicates that the polypeptide has been truncated in the fusion protein. * Peptides were synthesized using an automated peptide synthesizer (model 430A; Applied Biosystems). These peptides were purified to greater than 95 % purity, and the sequence was confirmed by using an amino acid analyser (model L-8500; Hitachi). PA-positive sera (a, b and c) in twofold dilutions were incubated with or without an oligopeptide (1.0 mg/ml) at 37 °C for 1 h, before the PA test.
~" Numbering indicates the amino acid position in the gag gene primary translation product.
Numbering indicates the amino acid position in the VZV gene 22 primary translation product. Fig. 3 . Immunoblots of anti-VZV sera and recombinant HTLV-1 p19 proteins. The vpr-pl 9 (27K) (a) and vpr-pl9M (23K) (b) proteins were expressed from plasmids pGEMEXRpl9 and pGEMEXRpl9M in lysogenic BL21 (DE3) cells (Studier & Moffatt, 1986) and analysed by WB. The first reaction contained guinea-pig anti-vpr serum (lanes 1), an HTLV-l-negative serum (lanes 2), an HTLV-l-positive serum (lanes 3) or anti-VZV sera (lanes 4 to 6). The second was done with HRPconjugated anti-human IgM (lanes 4 to 6) or Protein A-HRP (lanes 1 to 3). Arrowheads indicate the vpr-pl9 (a) and vpr-pl9M (b) proteins.
protein is known to be the p l 9 -t a x fusion protein in M T -2 cells ( K o b a y a s h i et al., 1984) , these findings suggested that most, if not all, PA-reactive a n t i -V Z V I g M antibodies are directed against the HTLV-1 gag p l 9 protein.
R e c o m b i n a n t p l 9 proteins expressed in Escherichia coli were then used as target antigens for W B analysis. A 27K fusion protein consisting of the N -t e r m i n a l 76 a m i n o acids of vpr o f h u m a n immunodeficiency virus type 1 ( H I V -I ) , the a m i n o acid sequence from positions 17 to 130 of HTLV-1 gag p l 9 and the a m i n o acid sequence from positions 131 to 144 of HTLV-1 gag p24 was produced (Fig. 2) . Fig. 3 shows representative results. The r e c o m b i n a n t 27K protein, v p r -p l 9 , was detected by using a guinea-pig anti-vpr serum (Fig. 3a,  lane l) and an H T L V -l -p o s i t i v e serum (lane 3), but not by using an H T L V -l -n e g a t i v e serum (lane 2). The v p rp l 9 fusion protein was also recognized by PA-positive a n t i -V Z V sera (lanes 4 and 5), but not by a P A -n e g a t i v e a n t i -V Z V serum (lane 6). W h e n a 23K fusion protein containing p19 with a truncation of the C -t e r m i n a l 17 amino acids, v p r -p l 9 M , was used as the target antigen for W B analysis (Fig. 3b) , it was recognized by the antivpr serum and the H T L V -l -p o s i t i v e serum 0aries 1 and 3, respectively), but not by any a n t i -V Z V serum, including those which were P A -p o s i t i v e (lanes 4 and 5). These results showed that a cross-reactive epitope Short communication recognized by PA-positive anti-VZV sera exists in the Cterminal 17 amino acids of p19.
Four oligopeptides corresponding to the C-terminal region of p19, p19(104-113), p19(107-119), p19(115-125) and p19(121-130) (Fig. 2, Table 3a ), were prepared and examined for reactivity with PA-positive anti-VZV sera by using the PA inhibition test. The PA titres of all PApositive anti-VZV sera was completely abolished by the p19(115-125) peptide, but not by the other three peptides. However, none of the peptides inhibited PA by HTLV-l-positive sera (Table 3) . Thus, the major epitope of p19 recognized by PA-positive anti-VZV sera is located between amino acids 115 and 125, PQIPPPY-VEPT. To localize the epitope further, we synthesized three heptapeptides, p19(115-121), p19(117-123) and p19(119-125) ( Table 3b ). None of these inhibited the PA reactivity of PA-positive anti-VZV sera, but they might be too short to have epitope activity.
Homology analysis of the amino acid sequence PQIPPPYVEPT was performed using the National Biomedical Research Foundation database (DNASIS; Hitachi). Amino acid sequences partially homologous to the above sequence, containing the IPPP tetrapeptide, were found in three human viruses, VZV, CMV and HSV-1 (two VZV proteins, two CMV proteins and one HSV-1 protein), but not in EBV, mumps virus, measles virus or rubella virus. Since cross-reactive IgM antibodies were found in only some anti-VZV sera but not in anti-CMV or anti-HSV-1 sera, the recognition of p 19 by anti-VZV IgM antibodies may be dependent not only on sequence homology between p19 and a VZV protein(s) but also on conformational similarity. To evaluate this notion, we analysed the structure of HTLV-1 p19, two VZV proteins, one HSV-1 protein and two CMV proteins in the region around the amino acid sequence IPPP (Chou & Fasman, 1978; Rose, 1978) . The predicted structure of the C terminus of the p19(115-125) peptide is a random coil structure up to IPPP, followed by a fl-sheet structure. The region of the VZV gene 22 protein (Davison & Scott, 1986 ) including IPPP had a conformation similar to that of the p19(115-125) peptide. However, the conformation of another VZV protein (immediate early protein IE68), one HSV-1 protein (UL36 protein) and two CMV proteins (hypothetical proteins UL63 and UL71) containing IPPP was quite different from that of p 19(115-125). Therefore we synthesized an oligopeptide including IPPP from the VZV gene 22 protein sequence, p(1330-1340), TNIPP-PLALLR, and examined its reactivity with anti-VZV IgM antibodies by the PA inhibition test. This peptide was found to be capable of completely inhibiting PA by all PA-positive anti-VZV sera, whereas it did not affect PA by anti-HTLV-1 sera (Table 3c ). Thus, we concluded that anti-VZV IgM antibodies cross-reactive with HTLV-1 p19 are mostly directed against the amino acid sequence of the VZV gene 22 protein containing the IPPP tetrapeptide.
In this study we have demonstrated frequent positive reactions in the PA test for anti-HTLV-1 antibodies (Fujino et al., 1991) with sera derived from acute VZV infections. IgM antibodies are mostly responsible for this cross-reactivity. This is probably because IgM antibodies usually are of lower affinity and much broader specificity than IgG antibodies. However, we do not consider the present results to indicate the antigen specificity of the PA test is poor compared to that of other anti-HTLV-1 tests. The presence of cross-reactive IgM antibodies can be demonstrated by other anti-HTLV-1 tests, such as the IF test (Hinuma et al., 1981) (data not shown) and the WB test (Fig. 1) , if one uses appropriately labelled anti-human IgM antibodies as the second antibody. The PA test is capable of detecting such cross-reactive IgM antibodies because it does not require second antibodies and because IgM antibodies are usually good agglutinins.
We have shown that cross-reactive IgM antibodies are produced specifically in VZV infections; sera derived from primary infections with other viruses were all negative. We further demonstrated that cross-reactive IgM antibodies are mostly directed to the HTLV-1 p19 gag protein and in particular to an epitope in the Cterminal amino acid sequence, PQIPPPYVEPT. By computer analysis, we have found a region having partial homology and a similar secondary structure in the VZV gene 22 protein amino acid sequence. We have shown that the VZV oligopeptide TNIPPPLALLR is capable of completely abolishing the reactivity of cross-reactive antibodies in anti-VZV sera. Therefore it is most likely that IgM antibodies directed to this region of the VZV gene 22 product are responsible for cross-reactivity with the C-terminal region of HTLV-1 p19. Our findings now provide a simple method of excluding the PA-reactivity of anti-VZV sera, i.e. absorption of cross-reactive antibodies using a VZV gene 22 oligopeptide. We also would like to note that cross-reactive antibodies are sometimes seen in blood samples from apparently healthy donors. Thirteen such samples which were negative for anti-HTLV-1 and anti-VZV IgM antibodies were tested for reactivity with p 19(115-125) and 12 were found to be positive. Therefore, the sequence IPPP might be a fairly common cross-reactive epitope in humans. The conditions or diseases other than VZV infection associated with the production of cross-reactive antibodies and what effects these antibodies may have on the host immune responses are not known.
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